The clinical progress of mRNA vaccines and immunotherapies

Ann Barbier(Translate Bio (United States)), Allen Yujie Jiang(Massachusetts Institute of Technology), Peng Zhang(Massachusetts Institute of Technology), Richard Wooster(Translate Bio (United States)), Daniel G. Anderson(Harvard–MIT Division of Health Sciences and Technology)
Nature Biotechnology
May 9, 2022
10.1038/s41587-022-01294-2
Cited by 761Open Access
Full Text

Abstract

Related Papers

Direct Gene Transfer into Mouse Muscle in Vivo
Jon A. Wolff, Robert W. Malone, Phillip Williams et al.|Science|1990|4.1k
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
Katalin Karikó, Michael Buckstein, Houping Ni et al.|Immunity|2005|2.6k
mRNA-based therapeutics — developing a new class of drugs
Uğur Şahin, Katalin Karikó, Özlem Türeci|Nature Reviews Drug Discovery|2014|2.4k
Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
Katalin Karikó, Hiromi Muramatsu, Frank A. Welsh et al.|Molecular Therapy|2008|1.8k
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akin Akinc, Andreas Zumbuehl, Michael S. Goldberg et al.|Nature Biotechnology|2008|1.2k